Literature DB >> 21446005

Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia.

Grégoire Robert1, Frank Smit, Daphne Hessels, Sander Jannink, Herbert F M Karthaus, Tilly Aalders, Kees Jansen, Alexandre de la Taille, Peter F Mulders, Jack A Schalken.   

Abstract

BACKGROUND: Chronic prostatic inflammation could be a central mechanism in benign prostatic hyperplasia (BPH) progression. Currently, the histological examination of prostate biopsies remains the only way to diagnose prostatic inflammation. Our objective was to find new noninvasive biomarkers for the diagnosis of prostatic inflammation.
METHODS: Ninety BPH samples were investigated in two steps. First, a hypothesis was generated using a profiling procedure with a panel of 96 genes on an initial set of 30 samples. Then, the candidate biomarkers were validated on a large number of samples (n = 90). Gene expression was compared with the histological prostatic inflammation score based on the density and the confluence of lymphoid nodules. Finally, protein transcripts of the candidate biomarkers were investigated in urine samples and compared with clinical data.
RESULTS: Of the 96 genes, nine were significantly correlated with the inflammation score on the initial set of patients. Four of them were validated on the complete set of patients: CCR7, CD40LG, CTLA4, and ICOS. ICOS and CTLA4 protein levels were readily measured in urine samples using a conventional ELISA procedure. High-ICOS expression in urine was associated with a higher post-void residual and a lower maximum urinary flow rate.
CONCLUSIONS: Four genes were significantly upregulated at the mRNA level in the prostate tissue of patients with severe inflammation score. Two proteins were measured in urine samples, and were associated with maximum uroflowmetry and post-void residual. A prospective clinical study is needed to confirm their clinical relevance.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21446005     DOI: 10.1002/pros.21387

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

1.  Correlation between systemic inflammatory response and quality of life in patients with chronic rhinosinusitis.

Authors:  Quinn Orb; Abigail Pulsipher; Kristine A Smith; Shaelene Ashby; Jeremiah A Alt
Journal:  Int Forum Allergy Rhinol       Date:  2019-01-18       Impact factor: 3.858

2.  Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Authors:  Ferenc G Rick; Andrew Abi-Chaker; Luca Szalontay; Roberto Perez; Miklos Jaszberenyi; Arumugam R Jayakumar; Nagarajarao Shamaladevi; Karoly Szepeshazi; Irving Vidaurre; Gabor Halmos; Awtar Krishan; Norman L Block; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

Review 3.  Inflammatory mediators in the development and progression of benign prostatic hyperplasia.

Authors:  Cosimo De Nunzio; Fabrizio Presicce; Andrea Tubaro
Journal:  Nat Rev Urol       Date:  2016-09-30       Impact factor: 14.432

4.  Intraurethral injection with LPS: an effective experimental model of prostatic inflammation.

Authors:  Fabiana Oliveira Dos Santos Gomes; Amanda Costa Oliveira; Edlene Lima Ribeiro; Bruna Santos da Silva; Laise Aline Martins Dos Santos; Ingrid Tavares de Lima; Amanda Karolina Soares E Silva; Shyrlene Meiry da Rocha Araújo; Terezinha Gonçalves; Mario Ribeiro de Melo-Junior; Christina Alves Peixoto
Journal:  Inflamm Res       Date:  2017-11-18       Impact factor: 4.575

Review 5.  The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review.

Authors:  Christina Alves Peixoto; Fabiana Oliveira Dos Santos Gomes
Journal:  J Inflamm (Lond)       Date:  2015-09-15       Impact factor: 4.981

6.  Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.

Authors:  Bettina Schlick; Petra Massoner; Angelika Lueking; Pornpimol Charoentong; Mirjam Blattner; Georg Schaefer; Klaus Marquart; Carmen Theek; Peter Amersdorfer; Dirk Zielinski; Matthias Kirchner; Zlatko Trajanoski; Mark A Rubin; Stefan Müllner; Peter Schulz-Knappe; Helmut Klocker
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

7.  Detection of Prostatic Inflammation From Peripheral Lymphocyte Count and Free/Total PSA Ratio in Men With LUTS/BPH.

Authors:  Xinyang Liao; Zhuang Tang; Jianzhong Ai; Hang Xu; Shiyu Zhang; Liangren Liu; Shi Qiu; Ping Tan; Yu Fan; Lu Yang; Qiang Wei
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

8.  Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.

Authors:  Alain Latil; Marie-Thérèse Pétrissans; Jérôme Rouquet; Grégoire Robert; Alexandre de la Taille
Journal:  Prostate       Date:  2015-08-26       Impact factor: 4.104

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.